Malignant Solid Tumors - Non Small Cell Lung Cancer research hub

A Phase 2, multicenter, randomized, open-label trial of GEN1046 as monotherapy and in combination with Pembrolizumab in subjects with relapsed/refractory metastatic non-small cell lung cancer after treatment with standard care therapy with a immune checkpoint inhibitor.

This study is testing a new drug called acasunlimab for people with advanced non-small cell lung cancer. It looks at whether taking acasunlimab on its own, or alongside an immunotherapy drug called pembrolizumab (Keytruda), can help shrink tumours after previous treatments have stopped working.